A Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa
Learn more at ClinicalTrials.gov – Identifier NCT04213261
For more information about the DeFi-Phase 3 Study, visit DeFi-RDEB.com |
